Pasar al contenido principal

DISEÑO DE UNA PLATAFORMA VACUNAL MULTIVALENTE BASADA EN LA VARIANTE 40FP8 DEL VIRUS DE LA FIEBRE DEL VALLE DEL RIFT

PID2021-122567OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publicación Artículo científico (JournalArticle)

Safety and Efficacy upon Infection in Sheep with Rift Valley Fever Virus ZH548-rA2, a Triple Mutant Rescued Virus

  • Moreno, Sandra
  • Lorenzo, Gema
  • López Valiñas, Álvaro
  • de la Losa, Nuria
  • Alonso, Celia
  • Charro, Elena
  • Núñez, José I.
  • Sánchez-Cordón, Pedro J.
  • Borrego, Belén
  • Brun, Alejandro
The introduction of three single nucleotide mutations into the genome of the virulent RVFV ZH548 strain allows for the rescue of a fully attenuated virus in mice (ZH548-rA2). These mutations are located in the viral genes encoding the RdRp and the non-structural protein NSs. This paper shows the results obtained after the subcutaneous inoculation of ZH548-rA2 in adult sheep and the subsequent challenge with the parental virus (ZH548-rC1). Inoculation with the ZH548-rA2 virus caused no detectable clinical or pathological effect in sheep, whereas inoculation of the parental rC1 virus caused lesions compatible with viral infection characterised by the presence of scattered hepatic necrosis. Viral infection was confirmed via immunohistochemistry, with hepatocytes within the necrotic foci appearing as the main cells immunolabelled against viral antigen. Furthermore, the inoculation of sheep with the rA2 virus prevented the liver damage expected after rC1 virus inoculation, suggesting a protective efficacy in sheep which correlated with the induction of both humoral and cell-mediated immune responses., This research was funded by grants AGL2017-83226-R and PID2021-122567OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF “A way of making Europe”., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Safety and Efficacy upon Infection in Sheep with Rift Valley Fever Virus ZH548-rA2, a Triple Mutant Rescued Virus

  • Moreno, Sandra
  • Lorenzo, Gema
  • López-Valiñas, Álvaro
  • de la Losa, Nuria
  • Alonso, Celia
  • Charro, Elena
  • Núñez, J. I.
  • Sánchez-Cordón, Pedro J.
  • Borrego, Belén
  • Brun Torres, Alejandro
14 Pág., The introduction of three single nucleotide mutations into the genome of the virulent RVFV ZH548 strain allows for the rescue of a fully attenuated virus in mice (ZH548-rA2). These mutations are located in the viral genes encoding the RdRp and the non-structural protein NSs. This paper shows the results obtained after the subcutaneous inoculation of ZH548-rA2 in adult sheep and the subsequent challenge with the parental virus (ZH548-rC1). Inoculation with the ZH548-rA2 virus caused no detectable clinical or pathological effect in sheep, whereas inoculation of the parental rC1 virus caused lesions compatible with viral infection characterised by the presence of scattered hepatic necrosis. Viral infection was confirmed via immunohistochemistry, with hepatocytes within the necrotic foci appearing as the main cells immunolabelled against viral antigen. Furthermore, the inoculation of sheep with the rA2 virus prevented the liver damage expected after rC1 virus inoculation, suggesting a protective efficacy in sheep which correlated with the induction of both humoral and cell-mediated immune responses., This research was funded by grants AGL2017-83226-R and PID2021-122567OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF “A way of making Europe”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Use of Rift Valley Fever Virus Expressing NanoLuc Luciferase for the Assessment of Neutralizing Antibodies and Antivirals

  • Borrego, Belén
  • Martínez-Sobrido, Luis
  • Brun, Alejandro
  • Nogales, Aitor
Protocol., Rift Valley fever (RVF) is an arboviral zoonotic disease affecting many African countries with the potential to spread to other geographical areas. In this chapter we describe the use of a replication-competent recombinant (r)RVFV expressing NanoLuc Luciferase (Nluc) for in vitro studies. The determination of parameters such as neutralizing antibodies in serum samples, or the antiviral activity of drugs is usually carried out using standard assays based on the assessment of cytopathic effect on cell cultures. The use of a virus encoding a traceable reporter protein allows to correlate the presence or absence of infection with the detection of the product in the infected cultures, thus tracking the level of RVFV infection in an objective, quantitative manner. In addition to this quantitative measurement of results, our protocol offers two other advantages, such as a shorter time to read, given that 48 h post-infection the production of the reporter protein is enough to give an accurate result, and the use of an attenuated virus, which reduces the risk of exposure., Research on RVFV was funded by grant PID2021-122567OB-I00 MCIN/AEI /10.13039/501100011033/ and by ERDF “A way of making Europe.” Research was also partially funded by ISIDORe JRA Programme. ISIDORe has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement number 101046133., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel replication-competent reporter-expressing Rift Valley fever viruses for molecular studies

  • Nogales, Aitor
  • Alonso, Celia
  • Moreno, Sandra
  • Lorenzo, Gema
  • Borrego, Belén
  • Martínez-Sobrido, Luis
  • Brun, Alejandro
All data supporting the findings of this study are available within the paper. No data sets or new viral sequences were generated or analyzed during the current study., Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic disease that causes severe disease in both domestic and wild ungulates and humans, making it a significant threat to livestock and public health. The RVFV genome consists of three single-stranded, negative-sense RNA segments differing in size: small (S), medium (M), and large (L). Segment S encodes the virus nucleoprotein N and the virulence-associated factor non-structural (NSs) protein in opposite orientations, separated by an intergenic region (IGR). To overcome the current need to use secondary techniques to detect the presence of RVFV in infected cells, we used T7-driven polymerase plasmid-based reverse genetics to generate replication-competent recombinant (r)RVFV expressing Nanoluciferase (Nluc) or Venus fluorescent proteins. These reporter genes were used as valid surrogates to track the presence of RVFV in mammalian and insect cells. Notably, we explored the genome plasticity of RVFV and compared four different strategies by modifying the viral segment S to introduce the reporter gene foreign sequences. The reporter-expressing rRVFV were stable and able to replicate in cultured mammalian and insect cells, although to a lesser extent than the recombinant wild-type (WT) counterpart. Moreover, rRVFV-expressing reporter genes were validated to identify neutralizing antibodies or compounds with antiviral activity. In vivo, all mice infected with the reporter-expressing rRVFV displayed an attenuated phenotype, although at different levels. These rRVFV-expressing reporter genes provide a novel approach to better understand the biology and pathogenesis of RVFV and represent an excellent biotechnological tool for developing new therapeutics against RVFV infections., This study was partially funded by the Ramon y Cajal Incorporation grant (RYC-2017) from the Spanish Ministry of Science, Innovation, and Universities and the European Union's Horizon Europe Research and Innovation Programme (grant agreement 101046133) and by grant PID2021-122567OB-I00 funded by MCIN/ AEI/10.13039/501100011033/and by ERDF “A way of making Europe.”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Single Dose of Live-Attenuated Rift Valley Fever Virus Vector Expressing Peste Des Petits Ruminants Virus (PPRV) H or F Antigens Induces Immunity in Sheep

  • Moreno, Sandra
  • Lorenzo, Gema
  • Martín, Verónica
  • Alonso, Celia
  • Weber, Friedemann
  • Borrego, Belén
  • Brun, Alejandro
This article belongs to the Special Issue Next-Generation Vaccines for Animal Infectious Diseases., [Introduction/Background] Rift Valley fever virus (RVFV) and peste des petits ruminants virus (PPRV) are significant pathogens affecting small ruminants, causing substantial economic losses in the affected regions. The development of effective vaccines against both viruses is crucial for disease control. Recombinant viruses expressing heterologous antigens have shown promise as multivalent vaccine candidates. Unlike conventional PPRV vaccines, our recombinant RVFV-vectored vaccines offer a novel dual-protection strategy against RVF and PPR, combining safety, immunogenicity, and a DIVA strategy., [Methods] Recombinant RVFVs (ZH548 strain) were generated to express either the hemagglutinin (H) or fusion (F) proteins from the PPRV strain Nigeria 75/1. The stability of these recombinant viruses was assessed through consecutive passages in cell culture. Immunogenicity studies were carried out in both mice and sheep to assess the induction of cellular and humoral immune responses capable of providing protection against RVFV and PPRV. These studies included intracellular cytokine staining (ICS), IFN-γ ELISAs, standard ELISAs for antibody detection, and virus neutralization assays., [Results] The recombinant RVFVs expressing PPRV H or F proteins demonstrated stability in cell culture, maintaining high viral titers and consistent transgene expression over four passages. Immunization of mice resulted in the production of serum antibodies capable of neutralizing both RVFV and PPRV in vitro as well as cell-mediated immune responses specific to PPRV and RVFV antigens. In mice vaccinated with a high dose (105 pfu), RVFV neutralizing titers reached ≥1:160 and PPRV neutralizing titers ranged from 1:40 to 1:80 by day 30 post-immunization. In sheep, neutralizing antibody titers against RVFV exceeded 1:160 as early as 2 days post-inoculation, while PPRV-specific neutralization titers reached up to 1:80 by day 21 in responsive individuals. In mice, administration of rZH548ΔNSs:FPPRV elicited a detectable CD8+ IFNγ+ T-cell response against PPRV, with levels ranging from 1.29% to 1.56% for the low and high doses, respectively. In sheep, rZH548ΔNSs:FPPRV also induced a robust IFNγ production against PPRV at 14 and 21 days post-infection (dpi)., [Conclusions] The successful generation and characterization of recombinant RVFVs expressing PPRV antigens demonstrate the potential of using rationally attenuated RVFV as a vector for multivalent vaccine development. Notably, the strategy proved more effective for the recombinant virus expressing the F protein, as it consistently induced more robust cellular and humoral immune responses. These results suggest that this approach could be a viable strategy for simultaneous immunization against Rift Valley fever and other prevalent ruminant diseases, such as peste des petits ruminants. Even though challenge studies were not performed in target species, the strong immune response observed supports including them in future studies., This research was funded by funded by MCIN/AEI/10.13039/501100011033, grant number AGL2017-83226-R and PID2021-122567OB-I00, and by Next Generation EU/PRTR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fiebre del Valle del Rift: enfermedad emergente en sanidad animal y zoonosis de relevancia global

  • Sánchez-Cordón, Pedro J.
  • Morán de Bustos, Sara
  • Pedrera, Miriam
  • Sánchez-Del Pozo, Iris
  • Alonso, Celia
  • Moreno, Sandra
  • Lorenzo, Gema
  • Rodríguez-Temporal, David
  • Rodríguez-Sánchez, Belén
  • Borrego, Belén
  • Brun, Alejandro
Información técnica., Proyectos PID2021-126593OB-I00 y PID2021-122567OB-I00 financiados por MICIU/AEI /10.13039/501100011033 y por FEDER, UE., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Safety and Efficacy upon Infection in Sheep with Rift Valley Fever Virus ZH548-rA2, a Triple Mutant Rescued Virus

  • Moreno, Sandra
  • Lorenzo, Gema
  • López Valiñas, Álvaro
  • de la Losa, Nuria
  • Alonso, Celia
  • Charro, Elena
  • Núñez, José I.
  • Sánchez-Cordón, Pedro J.
  • Borrego, Belén
  • Brun, Alejandro
The introduction of three single nucleotide mutations into the genome of the virulent RVFV ZH548 strain allows for the rescue of a fully attenuated virus in mice (ZH548-rA2). These mutations are located in the viral genes encoding the RdRp and the non-structural protein NSs. This paper shows the results obtained after the subcutaneous inoculation of ZH548-rA2 in adult sheep and the subsequent challenge with the parental virus (ZH548-rC1). Inoculation with the ZH548-rA2 virus caused no detectable clinical or pathological effect in sheep, whereas inoculation of the parental rC1 virus caused lesions compatible with viral infection characterised by the presence of scattered hepatic necrosis. Viral infection was confirmed via immunohistochemistry, with hepatocytes within the necrotic foci appearing as the main cells immunolabelled against viral antigen. Furthermore, the inoculation of sheep with the rA2 virus prevented the liver damage expected after rC1 virus inoculation, suggesting a protective efficacy in sheep which correlated with the induction of both humoral and cell-mediated immune responses., This research was funded by grants AGL2017-83226-R and PID2021-122567OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by ERDF “A way of making Europe”., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Safety and Efficacy upon Infection in Sheep with Rift Valley Fever Virus ZH548-rA2, a Triple Mutant Rescued Virus

  • Moreno, Sandra|||0000-0002-3548-037X
  • Lorenzo, Gema
  • López-Valiñas, Álvaro
  • de la Losa, Nuria
  • Alonso, Celia
  • Charro, Elena
  • Núñez, J. Ignacio|||0000-0001-9890-7695
  • Sánchez-Cordón, Pedro J.|||0000-0002-7202-6475
  • Borrego, Belén|||0000-0002-0801-9166
  • Brun, Alejandro
The introduction of three single nucleotide mutations into the genome of the virulent RVFV ZH548 strain allows for the rescue of a fully attenuated virus in mice (ZH548-rA2). These mutations are located in the viral genes encoding the RdRp and the non-structural protein NSs. This paper shows the results obtained after the subcutaneous inoculation of ZH548-rA2 in adult sheep and the subsequent challenge with the parental virus (ZH548-rC1). Inoculation with the ZH548-rA2 virus caused no detectable clinical or pathological effect in sheep, whereas inoculation of the parental rC1 virus caused lesions compatible with viral infection characterised by the presence of scattered hepatic necrosis. Viral infection was confirmed via immunohistochemistry, with hepatocytes within the necrotic foci appearing as the main cells immunolabelled against viral antigen. Furthermore, the inoculation of sheep with the rA2 virus prevented the liver damage expected after rC1 virus inoculation, suggesting a protective efficacy in sheep which correlated with the induction of both humoral and cell-mediated immune responses.